CD84 is markedly up-regulated in Kawasaki disease arteriopathy

Clinical and Experimental Immunology

Volumn 177, Issue 1, 2014, Pages 203-211

  Reindel, R ^a   Bischof, J ^b,g   Kim, K Y A ^a   Orenstein, J M ^e   Soares, M B ^a,b   Baker, S C ^d   Shulman, S T ^a   Perlman, E J ^a   Lingen, M W ^c   Pink, A J ^a   Trevenen, C ^f   Rowley, A H ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Ann and Robert H Lurie Children's Hospital of Chicago   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

^e GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^f ALBERTA CHILDREN'S HOSPITAL   (Canada)

^g UNIVERSITY OF CHICAGO   (United States)

Author keywords

CD84; Coronary artery aneurysm; Inflammation; Kawasaki disease; Vasculitis

Indexed keywords

CD150 ANTIGEN; CD84 ANTIGEN; CYCLOPHOSPHAMIDE; GAMMA GLUTAMYL HYDROLASE; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 10 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR ALPHA; LYMPHOCYTE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SRC KINASE ASSOCIATED PHOSPHOPROTEIN 2; STEROID; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ARTICLE; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; FEMALE; GENE EXPRESSION; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; INFANT; MALE; MOLECULAR PATHOLOGY; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; STEROID THERAPY; THROMBOCYTE AGGREGATION; UPREGULATION;

CD84; CORONARY ARTERY ANEURYSM; INFLAMMATION; KAWASAKI DISEASE; VASCULITIS;

ACUTE DISEASE; ANTIGENS, CD; ANTIGENS, NUCLEAR; BLOOD PLATELETS; CELL GROWTH PROCESSES; CELL MOVEMENT; CELL SURVIVAL; CHRONIC DISEASE; CORONARY VESSELS; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYXOVIRUS RESISTANCE PROTEINS; PLATELET AGGREGATION; RNA, MESSENGER; TRANSCRIPTION FACTORS; UP-REGULATION; VASCULAR CALCIFICATION;

EID: 84904240607     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12327     Document Type: Article

References (38)

1. Newburger JW, Takahashi M, Gerber MA etal. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110:2747-2771.
2. Orenstein JM, Shulman ST, Fox LM etal. Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study. PLOS ONE 2012; 7:e38998.
3. Amano S, Hazama F, Hamashima Y. Pathology of Kawasaki disease: II. Distribution and incidence of the vascular lesions. Jpn Circ J 1979; 43:741-748.
4. Fujiwara H, Hamashima Y. Pathology of the heart in Kawasaki disease. Pediatrics 1978; 61:100-107.
5. Newburger JW, Takahashi M, Beiser AS etal. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324:1633-1639.
6. Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW. Gamma globulin re-treatment in Kawasaki disease. J Pediatr 1993; 123:657-659.
7. Tremoulet AH, Best BM, Song S etal. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 2008; 153:117-121.
8. Printz BF, Sleeper LA, Newburger JW etal. Noncoronary cardiac abnormalities are associated with coronary artery dilation and with laboratory inflammatory markers in acute Kawasaki disease. J Am Coll Cardiol 2011; 57:86-92.
9. Rosenfeld EA, Corydon KE, Shulman ST. Kawasaki disease in infants less than one year of age. J Pediatr 1995; 126:524-529.
10. Burns JC, Wiggins JW Jr, Toews WH etal. Clinical spectrum of Kawasaki disease in infants younger than 6 months of age. J Pediatr 1986; 109:759-763.
11. Yahata T, Suzuki C, Yoshioka A, Hamaoka A, Ikeda K. Platelet activation dynamics evaluated using platelet-derived microparticles in Kawasaki disease. Circ J 2013; 78:188-193.
12. Storey JD. A direct approach to false discovery rates. J R Stat Soc Ser B Stati Methodol 2002; 64:479-498.
13. Reindel R, Baker SC, Kim KY etal. Integrins alpha4 and alphaM, collagen1A1, and matrix metalloproteinase 7 are up-regulated in acute Kawasaki disease vasculopathy. Pediatr Res 2013; 73:332-336.
14. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3:1101-1108.
15. Brown TJ, Crawford SE, Cornwall ML, Garcia F, Shulman ST, Rowley AH. CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J Infect Dis 2001; 184:940-943.
16. Krause SW, Rehli M, Heinz S, Ebner R, Andreesen R. Characterization of MAX.3 antigen, a glycoprotein expressed on mature macrophages, dendritic cells and blood platelets: identity with CD84. Biochem J 2000; 346:729-736.
17. Romero X, Benitez D, March S, Vilella R, Miralpeix M, Engel P. Differential expression of SAP and EAT-2-binding leukocyte cell-surface molecules CD84, CD150 (SLAM), CD229 (Ly9) and CD244 (2B4). Tissue Antigens 2004; 64:132-144.
18. Cannons JL, Qi H, Lu KT etal. Optimal germinal center responses require a multistage T cell:B cell adhesion process involving integrins, SLAM-associated protein, and CD84. Immunity 2010; 32:253-265.
19. Yan Q, Malashkevich VN, Fedorov A etal. Structure of CD84 provides insight into SLAM family function. Proc Natl Acad Sci USA 2007; 104:10583-10588.
20. Nanda N, Andre P, Bao M etal. Platelet aggregation induces platelet aggregate stability via SLAM family receptor signaling. Blood 2005; 106:3028-3034.
21. Phillips DR, Conley PB, Sinha U, Andre P. Therapeutic approaches in arterial thrombosis. J Thromb Haemost 2005; 3:1577-1589.
22. Amano S, Hazama F, Hamashima Y. Pathology of Kawasaki disease: I. Pathology and morphogenesis of the vascular changes. Jpn Circ J 1979; 43:633-643.
23. Satoda M, Tatsukawa H, Katoh S. Images in cardiovascular medicine. Sudden death due to rupture of coronary aneurysm in a 26-year-old man. Circulation 1998; 97:705-706.
24. Kuijpers TW, Biezeveld M, Achterhuis A etal. Longstanding obliterative panarteritis in Kawasaki disease: lack of cyclosporin A effect. Pediatrics 2003; 112:986-992.
25. Heaton P, Wilson N. Fatal Kawasaki disease caused by early occlusive coronary artery disease. Arch Dis Child 2002; 87:145-146.
26. Rowley AH, Baker SC, Shulman ST etal. RNA-containing cytoplasmic inclusion bodies in ciliated bronchial epithelium months to years after acute Kawasaki disease. PLOS ONE 2008; 3:e1582.
27. Rowley AH, Baker SC, Shulman ST etal. Ultrastructural, immunofluorescence, and RNA evidence support the hypothesis of a 'new' virus associated with Kawasaki disease. J Infect Dis 2011; 203:1021-1030.
28. Onouchi Y, Gunji T, Burns JC etal. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet 2008; 40:35-42.
29. Melen K, Keskinen P, Ronni T, Sareneva T, Lounatmaa K, Julkunen I. Human MxB protein, an interferon-alpha-inducible GTPase, contains a nuclear targeting signal and is localized in the heterochromatin region beneath the nuclear envelope. J Biol Chem 1996; 271:23478-23486.
30. Madani N, Millette R, Platt EJ etal. Implication of the lymphocyte-specific nuclear body protein Sp140 in an innate response to human immunodeficiency virus type 1. J Virol 2002; 76:11133-11138.
31. Regad T, Chelbi-Alix MK. Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene 2001; 20:7274-7286.
32. Alenghat FJ, Baca QJ, Rubin NT etal. Macrophages require Skap2 and Sirpalpha for integrin-stimulated cytoskeletal rearrangement. J Cell Sci 2012; 125:5535-5545.
33. Reinhold A, Reimann S, Reinhold D, Schraven B, Togni M. Expression of SKAP-HOM in DCs is required for an optimal immune response in vivo. J Leukoc Biol 2009; 86:61-71.
34. Tomizawa T, Kaneko Y, Saito Y etal. Resistance to experimental autoimmune encephalomyelitis and impaired T cell priming by dendritic cells in Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 mutant mice. J Immunol 2007; 179:869-877.
35. Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med 2007; 356:2622-2629.
36. Filippini G, Del Giovane C, Vacchi L etal. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev 2013; (6):CD008933.
37. Kane SV, Horst S, Sandborn WJ etal. Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. Inflamm Bowel Dis 2012; 18:2203-2208.
38. Onouchi Y, Tamari M, Takahashi A etal. A genomewide linkage analysis of Kawasaki disease: evidence for linkage to chromosome 12. J Hum Genet 2007; 52:179-190.